Advanced Search

Technical Analysis for RGLS - Regulus Therapeutics Inc.

Grade Last Price % Change Price Change
D 1.4 2.94% 0.04
RGLS closed up 2.94 percent on Thursday, April 15, 2021, on 68 percent of normal volume.
6 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical RGLS trend table...
Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Bullish Engulfing Bullish 2.94%
Stochastic Buy Signal Bullish 2.94%
Pocket Pivot Bullish Swing Setup 2.94%
Lower Bollinger Band Walk Weakness 2.94%
Outside Day Range Expansion 2.94%
Wide Bands Range Expansion 2.94%
Lower Bollinger Band Touch Weakness 2.94%
Oversold Stochastic Weakness 2.94%
Older End-of-Day Signals for RGLS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above 10 DMA about 12 hours ago
Rose Above Previous Day's High about 12 hours ago
10 DMA Resistance about 12 hours ago
Up 5% about 12 hours ago
Up 3% about 12 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators Basic chart:

Profile

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diseases Genetics Blastoma Carcinoma Glioblastoma Hepatitis C Glaxosmithkline Oligonucleotide Hepatitis C Virus Regulus Therapeutics Hepatocellular Carcinoma RNA Nucleic Acids Alnylam Pharmaceuticals Nucleotides Hepatitis C Virus Infection Atherosclerosis Microrna

Is RGLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Apr 15 Regulus Therapeutics completes dosing in early-stage kidney disease trial
Apr 15 Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Apr 7 Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Mar 10 Investors Who Bought Regulus Therapeutics (NASDAQ:RGLS) Shares A Year Ago Are Now Up 101%
Mar 9 Regulus Therapeutics EPS of -$0.03
Mar 9 Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates
Mar 5 Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Mar 4 Will Regulus (RGLS) Report Negative Q4 Earnings? What You Should Know
Feb 10 Regulus Therapeutics gains on completion of enrollment in study of RGLS4326 for kidney disease
Feb 10 Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
See more RGLS news...

Indicators

Indicator Value
52 Week High 2.32
52 Week Low 0.4222
Average Volume 3,517,007
200-Day Moving Average 0.97
50-Day Moving Average 1.55
20-Day Moving Average 1.52
10-Day Moving Average 1.42
Average True Range 0.18
ADX 17.44
+DI 15.77
-DI 20.99
Chandelier Exit (Long, 3 ATRs ) 1.35
Chandelier Exit (Short, 3 ATRs ) 1.70
Upper Bollinger Band 1.83
Lower Bollinger Band 1.21
Percent B (%b) 0.31
BandWidth 40.96
MACD Line -0.06
MACD Signal Line -0.03
MACD Histogram -0.0257
Fundamentals Value
Market Cap 54.83 Million
Num Shares 39.2 Million
EPS -2.43
Price-to-Earnings (P/E) Ratio -0.58
Price-to-Sales 3.94
Price-to-Book 3.54
PEG Ratio -0.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.76
Resistance 3 (R3) 1.74 1.61 1.70
Resistance 2 (R2) 1.61 1.51 1.62 1.68
Resistance 1 (R1) 1.50 1.46 1.56 1.52 1.66
Pivot Point 1.37 1.37 1.39 1.38 1.37
Support 1 (S1) 1.26 1.27 1.32 1.28 1.14
Support 2 (S2) 1.13 1.22 1.14 1.12
Support 3 (S3) 1.02 1.13 1.10
Support 4 (S4) 1.04